Mengis Capital Management, Inc. Incyte Corp Transaction History

Mengis Capital Management, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$67.18 - $84.11 $214,976 - $269,152	-3,200 Reduced 27.41%	8,475 $680,000
Q3 2022 Nov 04, 2022	SELL	$66.18 - $82.86 $158,832 - $198,864	-2,400 Reduced 17.05%	11,675 $778,000
Q2 2022 Jul 19, 2022	SELL	$66.18 - $83.18 $52,944 - $66,544	-800 Reduced 5.38%	14,075 $1.07 Million
Q1 2022 May 02, 2022	SELL	$66.02 - $79.71 $26,408 - $31,883	-400 Reduced 2.62%	14,875 $1.18 Million
Q4 2021 Feb 04, 2022	SELL	$63.34 - $74.11 $31,670 - $37,055	-500 Reduced 3.17%	15,275 $1.12 Million
Q3 2021 Nov 03, 2021	SELL	$68.67 - $84.02 $39,828 - $48,731	-580 Reduced 3.55%	15,775 $1.09 Million
Q4 2020 Feb 03, 2021	BUY	$80.74 - $97.7 $78,721 - $95,257	975 Added 6.34%	16,355 $1.42 Million
Q3 2020 Oct 29, 2020	SELL	$85.07 - $109.69 $8,507 - $10,969	-100 Reduced 0.65%	15,380 $1.38 Million
Q2 2020 Jul 22, 2020	BUY	$74.18 - $108.93 $7,418 - $10,893	100 Added 0.65%	15,480 $1.61 Million
Q1 2020 May 06, 2020	BUY	$63.18 - $85.97 $69,498 - $94,567	1,100 Added 7.7%	15,380 $1.13 Million
Q4 2019 Feb 06, 2020	BUY	$73.04 - $95.72 $357,896 - $469,028	4,900 Added 52.24%	14,280 $1.25 Million
Q3 2019 Nov 05, 2019	BUY	$72.82 - $86.52 $493,719 - $586,605	6,780 Added 260.77%	9,380 $696,000
Q2 2019 Jul 18, 2019	BUY	$73.52 - $88.7 $191,152 - $230,620	2,600 New	2,600 $220,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Mengis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Mengis Capital Management, Inc. with notifications on news.